Physician profile
Mark Douglas Statler
NPI 1164475604
$3,373.49
in general payments reported to CMS, 2019-2025
29 companies · $536 in 2025
The $536 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $292 · 2021: $245 · 2022: $293 · 2023: $774 · 2024: $484 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,793.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $397.20 | 2019-2023 | Octrode |
| Medtronic, INC. | $332.47 | 2022-2025 | Kyphon Express II Kyphopak Tray, Inceptiv |
| Ironshore Pharmaceuticals INC. | $289.77 | 2019 | |
| Amgen INC. | $280.18 | 2023-2025 | Tavneos, Repatha |
| Teva Pharmaceuticals USA, INC. | $260.74 | 2020 | |
| Abbvie INC. | $231.65 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $213.67 | 2021-2024 | Qelbree, Qelbree |
| Sanofi Pasteur INC. | $181.84 | 2019-2023 | |
| Si-Bone, INC. | $161.32 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $131.40 | 2023 | |
| Biogen, INC. | $122.08 | 2019 | |
| Alexion Pharmaceuticals, INC. | $116.24 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.42 | 2024 | |
| Acadia Pharmaceuticals INC | $97.43 | 2023-2024 | Daybue |
| Cranial Technologies, INC | $85.48 | 2021-2024 | Doc Band |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $72.99 | 2020-2021 | |
| Pfizer INC. | $44.25 | 2021-2024 | |
| Avion Pharmaceuticals | $35.50 | 2023 | Methylphenidate Hydrochloride |
| Adlon Therapeutics L.P. | $32.77 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $31.64 | 2019-2021 | |
| Corium, LLC | $22.71 | 2022-2023 | Azstarys |
| Glaxosmithkline, LLC. | $17.85 | 2023 | Bexsero |
| Verrica Pharmaceuticals INC. | $17.03 | 2024 | Ycanth |
| Mission Pharmacal Company | $15.49 | 2019 | |
| Tris Pharma INC | $15.13 | 2019 | |
| Shire North American Group INC | $14.56 | 2019 | |
| Alk-Abello, INC | $14.46 | 2023 | Odactra, Grastek, Ragwitek |
| Genentech USA, INC. | $13.67 | 2020 | |
| Vertical Pharmaceuticals, LLC | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Statler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.